DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 71 · March 2017 DOI: 10.1055/s-007-33496

58. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.

IC Stuttgart, 22.–25.03.2017
Kongresspräsidenten: Prof. Dr. med. Martin Hetzel, Stuttgart, Prof. Dr. med. Martin Kohlhäufl, Gerlingen; Kongresssekretär: Dr. med. Markus Zenner, Stuttgart


P30
Kreuter, M; Wacker, M; Hammerl, P; Wiederhold, C; Kabitz, HJ; Hagmeyer, L; Skowasch, D; Leidl, R; Hellmann, A; Pfeifer, M; Behr, J; Witt, S; Kauschka, D; Mall, M; Günther, A; Herth, FJF; Markart, P: Interims Analyse des EXCITING-ILD Registers (Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases)
P38
Kreuter, M; Bonella, F; Maher, TM; Costabel, U; Spagnolo, P; Weycker, D; Kirchgaessler, KU; Kolb, M: Impact of statins on lung function decline in idiopathic pulmonary fibrosis (IPF)
P51
Costabel, U; Nathan, SD; Lancaster, L; Albera, C; Glassberg, MK; Swigris, JJ; Gilberg, F; Kirchgaessler, KU; Petzinger, U; Noble, PW: Dose modifications and dose intensity during treatment with pirfenidone
P55
van Manen, M; Birring, SS; Vancheri, C; Wapenaar, M; Cottin, V; Wijsenbeek, MJG: Effect of Pirfenidone on cough in patients with Idiopathic Pulmonary Fibrosis
P173
P175
Behr, J; Raghu, G; Inoue, Y; Cottin, V; Stowasser, S; Stansen, W; Maher, TM: Effect of nintedanib on disease progression in the INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF)
P177
Kreuter, M; Crestani, B; Quaresma, M; Kaye, M; Stansen, W; Stowasser, S: Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS-ON
P178
Neurohr, C; Richeldi, L; Azuma, A; Selman, M; Tang, W; Capapey, J; Stowasser, S; Cottin, V: Twenty-four week decline in forced vital capacity (FVC) predicts mortality at week 52 in the INPULSIS trials
P179
Pfeifer, M; Maher, TM; Flaherty, KR; Inoue, Y; Richeldi, L; Selman, M; Stansen, W; Stowasser, S; Wells, A: No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib
P202